CL2010001151A1 - Formulation comprising the nhe, che, nnp, m1 and fp2 protein segments of the isa virus; recombinant vaccine that comprises it; preparation procedure; and use to prevent or treat isa virus infection. - Google Patents

Formulation comprising the nhe, che, nnp, m1 and fp2 protein segments of the isa virus; recombinant vaccine that comprises it; preparation procedure; and use to prevent or treat isa virus infection.

Info

Publication number
CL2010001151A1
CL2010001151A1 CL2010001151A CL2010001151A CL2010001151A1 CL 2010001151 A1 CL2010001151 A1 CL 2010001151A1 CL 2010001151 A CL2010001151 A CL 2010001151A CL 2010001151 A CL2010001151 A CL 2010001151A CL 2010001151 A1 CL2010001151 A1 CL 2010001151A1
Authority
CL
Chile
Prior art keywords
isa virus
formulation
prevent
recombinant vaccine
nnp
Prior art date
Application number
CL2010001151A
Other languages
Spanish (es)
Inventor
Sebastian Valenzuela
Vivian Wilhelm
Luis Burzio
Pablo Valenzuela
Original Assignee
Fund Ciencia Para La Vida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fund Ciencia Para La Vida filed Critical Fund Ciencia Para La Vida
Priority to CL2010001151A priority Critical patent/CL2010001151A1/en
Publication of CL2010001151A1 publication Critical patent/CL2010001151A1/en

Links

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Una formulación que comprende los segmentos proteicos NHE, CHE, NNP, M1 y el segmento proteico FP2, de virus ISA. Una vacuna recombinante que comprende a dicha formulación. Uso de dicha formulación para prevenir o proteger a un vertebrado de la infección por virus ISA. Uso de dicha vacuna recombinante para prevenir o proteger a un vertebrado de la infección por virus ISA. Un procedimiento para la preparación de dicha vacuna recombinante que comprende las etapas listadas en el pliego de reivindicaciones.A formulation comprising the NHE, CHE, NNP, M1 protein segments and the FP2 protein segment of ISA virus. A recombinant vaccine comprising said formulation. Use of said formulation to prevent or protect a vertebrate from infection with ISA virus. Use of said recombinant vaccine to prevent or protect a vertebrate from infection with ISA virus. A process for the preparation of said recombinant vaccine comprising the steps listed in the statement of claims.

CL2010001151A 2010-10-20 2010-10-20 Formulation comprising the nhe, che, nnp, m1 and fp2 protein segments of the isa virus; recombinant vaccine that comprises it; preparation procedure; and use to prevent or treat isa virus infection. CL2010001151A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CL2010001151A CL2010001151A1 (en) 2010-10-20 2010-10-20 Formulation comprising the nhe, che, nnp, m1 and fp2 protein segments of the isa virus; recombinant vaccine that comprises it; preparation procedure; and use to prevent or treat isa virus infection.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CL2010001151A CL2010001151A1 (en) 2010-10-20 2010-10-20 Formulation comprising the nhe, che, nnp, m1 and fp2 protein segments of the isa virus; recombinant vaccine that comprises it; preparation procedure; and use to prevent or treat isa virus infection.

Publications (1)

Publication Number Publication Date
CL2010001151A1 true CL2010001151A1 (en) 2012-08-03

Family

ID=66221151

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2010001151A CL2010001151A1 (en) 2010-10-20 2010-10-20 Formulation comprising the nhe, che, nnp, m1 and fp2 protein segments of the isa virus; recombinant vaccine that comprises it; preparation procedure; and use to prevent or treat isa virus infection.

Country Status (1)

Country Link
CL (1) CL2010001151A1 (en)

Similar Documents

Publication Publication Date Title
CL2016002269A1 (en) Allosteric modulators of the hepatitis core protein b.
CO2017006580A2 (en) Human Antibodies to Influenza Hemagglutinin
CL2018000684A1 (en) Modulators of hepatitis core protein b.
CL2016002179A1 (en) New 6-fused heteroaryl dihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection.
CL2016000493A1 (en) Hcv polymerase inhibitors
CO2017007619A2 (en) Human antibodies against Ebola virus glycoprotein
CL2016003056A1 (en) Sting modulating cyclic dinucleotides; Composition and pharmaceutical combination that includes them and their use for the treatment of diseases such as inflammation, allergic and autoimmune diseases, infectious diseases and cancer.
ECSP14013315A (en) VIRAL APPLICATION INHIBITORS
CL2016000381A1 (en) Antiviral compounds
CL2015000942A1 (en) Compounds of substituted benzene.
GT201500020A (en) SULFAMOILARILAMIDAS AND ITS USE AS MEDICINES FOR THE TREATMENT OF HEPATITIS B
CL2015003298A1 (en) Novel bridged heteroaryl dihydropyrimidines in 6 for the treatment and prophylaxis of hepatitis B virus infection
UY37741A (en) INDOLINA DERIVATIVES REPLACED AS INHIBITORS OF THE DENGUE VIRUS REPLICATION
CL2013003019A1 (en) Compounds derived from benzothiazole; pharmaceutical composition that includes them; and its use in the treatment of hiv.
CL2015001756A1 (en) Compounds derived from polycyclic carbamoylpyridone; pharmaceutical composition that includes them; and its use for the treatment of a hiv infection in a human who has or is at risk of having the infection.
CL2014003634A1 (en) Hepatitis C virus inhibitors
CL2012001959A1 (en) Compounds derived from thiophene-2-carboxylic acid, flaviviridae virus inhibitors; pharmaceutical composition that includes them; and its use for the treatment of a viral infection by flaviviridae.
CL2016001918A1 (en) Heteroaryl amides as protein aggregation inhibitors
CY1117214T1 (en) COMPOSITION FOR CONTROLLED OVENTION STUDY
CL2012000573A1 (en) Compounds derived from biphenyl-pyrrolidinyl-imidazole; pharmaceutical composition comprising them; its use in the treatment of an hcv viral infection.
BR112012020839A2 (en) vaccines for use in the prophylaxis and treatment of influenza virus disease
CL2013001141A1 (en) Compounds derived from condensed heterocycles, hepatitis c virus inhibitors; pharmaceutical composition that contains them; and its use for the treatment of hepatitis c virus infection.
DOP2016000336A (en) ISOINDOLIN DERIVATIVES FOR USE IN THE TREATMENT OF A VIRAL INFECTION
CL2016000300A1 (en) Therapeutic methods
CR20160178A (en) DEOXINOJIRIMICINE DERIVATIVES AND THEIR METHODS OF USE